Skip to main
BCDA
BCDA logo

BioCardia Inc. (BCDA) Stock Forecast & Price Target

BioCardia Inc. (BCDA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioCardia Inc. is advancing its CardiAMP autologous mononuclear cell therapy platform, showing significant reductions in heart-related death equivalents and major adverse cardiovascular and cerebrovascular events (MACCE) in high-risk patients, as demonstrated in their Phase 3 CardiAMPHF clinical trial. The company's therapies are particularly impactful for patients with elevated NTproBNP levels, indicating potential long-term benefits that may mitigate disease progression. With a focus on addressing unmet medical needs in cardiovascular and pulmonary diseases, BioCardia’s clinical advancements suggest a promising outlook driven by strong patient outcomes and a diversified therapeutic approach.

Bears say

BioCardia Inc. faces significant challenges as its CardiAMP autologous mononuclear cell therapy did not meet its primary three-tiered composite endpoint in the Phase 3 trial, limiting its prospects for clinical success. This unmet milestone raises concerns regarding the viability of its clinical programs, including the CardiALLO platform, which remains unforecasted in financial projections due to uncertainty. Additionally, the company's reliance on securing adequate funding and potential risks related to capital raises contribute to a negative outlook on its long-term financial stability and growth potential.

BioCardia Inc. (BCDA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioCardia Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioCardia Inc. (BCDA) Forecast

Analysts have given BioCardia Inc. (BCDA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioCardia Inc. (BCDA) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioCardia Inc. (BCDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.